Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) open the trading on Thursday, with great promise as it jumped 2.94% to $69.59, before settling in for the price of $67.6 at the close. Taking a more long-term approach, ARWR posted a 52-week range of $9.57-$76.76.
It was noted that the giant of the Healthcare sector posted annual sales growth of 57.10% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 57.10%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -32569.92%. This publicly-traded company’s shares outstanding now amounts to $135.70 million, simultaneously with a float of $125.87 million. The organization now has a market capitalization sitting at $9.46 billion.
Arrowhead Pharmaceuticals Inc (ARWR) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Arrowhead Pharmaceuticals Inc’s current insider ownership accounts for 7.37%, in contrast to 81.04% institutional ownership. According to the most recent insider trade that took place on Jan 05 ’26, this organization’s COO sold 49,493 shares at the rate of 63.11, making the entire transaction reach 3,123,349 in total value, affecting insider ownership by 474,908. Preceding that transaction, on Jan 05 ’26, Company’s Chief Medical Officer sold 40,164 for 63.11, making the whole transaction’s value amount to 2,534,661. This particular insider is now the holder of 171,958 in total.
Arrowhead Pharmaceuticals Inc (ARWR) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.95 per share during the current fiscal year. Arrowhead Pharmaceuticals Inc’s EPS decrease for this current 12-month fiscal period is -32569.92% and is forecasted to reach -4.20 in the upcoming year.
Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Trading Performance Indicators
Let’s observe the current performance indicators for Arrowhead Pharmaceuticals Inc (ARWR). It’s Quick Ratio in the last reported quarter now stands at 4.86. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 11.40. Similarly, its price to free cash flow for trailing twelve months is now 60.27.
In the same vein, ARWR’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.07, a figure that is expected to reach 0.04 in the next quarter, and analysts are predicting that it will be -4.20 at the market close of one year from today.
